# Nestle is building a product line around GLP-1 muscle loss. Here is what the evidence says.

> Source: https://peptidewellnessusa.com/news/glp-1-muscle-loss-nestle-august-2026/
> News · Industry · August 2026
> By PeptideWellness Editorial Team · Updated August 18, 2026 · 7 min read

Nestle says it is building products for people on Ozempic and Wegovy, starting with the muscle they lose. The loss is real and well measured — but only one intervention reliably reduces it.

On August 17, 2026, Reuters published an interview with Stefan Palzer, Nestle's Executive Vice President and Chief Technology Officer, describing how the world's largest food company intends to sell to people on GLP-1 drugs instead of losing them as customers. The hook is not appetite. It is what the bathroom scale does not show: the muscle that leaves along with the fat. That framing deserves to be taken seriously, because the problem is real and unusually well measured. Whether the products answer it is a separate question — and the trial evidence has a fairly specific answer.

## What was said, and where it exists

Palzer told Reuters that Nestle is using artificial intelligence to read clinical literature and identify nutrient combinations aimed at GLP-1 users, calling it "a huge opportunity for our company." Presentation materials shown to the reporter listed side effects of rapid weight loss — muscle loss and the facial fat loss popularly called "Ozempic face" — alongside areas where Nestle believes its portfolio can help. Named products include a Boost Advanced Nutrition Shake marketed on 35 grams of protein, a higher-protein Milo PRO in Asia and Australia, and collagen added to Vital Proteins items.

One point of housekeeping matters for how much weight to put on this. As of publication, Nestle has issued no press release describing a GLP-1 product line, and its half-year 2026 results do not mention GLP-1 drugs at all. We checked the company's press releases, its news archive, and Nestle USA's releases. This story exists as an executive interview and a slide deck shown to one journalist — not as a filing, a launch, or a disclosed R&D program. That is worth knowing before treating any of it as a commitment.

## The muscle problem is real, and larger than most patients are told

Two 2026 evidence syntheses have now put numbers on this. A systematic review in Annals of Internal Medicine, from a team including body-composition researcher Carla Prado, screened 8,102 records and analysed 35 trials of liraglutide, semaglutide, tirzepatide and dulaglutide. Within the drug groups, the median share of total weight loss attributable to muscle-based measures was 28.3 percent, with an interquartile range of 15.9 to 39.9 percent. Two thirds of the interventions exceeded the review's prespecified benchmark of roughly 25 percent.

A meta-analysis in Diabetes, Obesity and Metabolism pooled 20 randomised trials covering 15,782 participants and broke the figure out by drug. Lean mass accounted for 35.2 percent of weight lost on semaglutide, 25.4 percent on tirzepatide and 26.8 percent on liraglutide. So the marketing premise is sound: a meaningful fraction of what a GLP-1 patient loses is not fat. Nestle's slide deck is describing something that shows up in DXA and MRI, not a manufactured worry.

## The part that undercuts the pitch

The same meta-analysis compared those drugs against intensive lifestyle programmes, and this is where the story turns. Losing weight by diet and behaviour change cost participants 26.2 percent of their loss as lean mass — statistically indistinguishable from the drugs, at p = 0.42. The one arm that came out materially better was lifestyle plus resistance training, at 17.5 percent. The Annals review reached a compatible conclusion from the other direction: the benchmarks were exceeded in nearly half of the non-drug interventions too.

| Approach | Share of weight lost that was lean mass |
| --- | --- |
| Semaglutide | 35.2% (95% CI 31.5–38.9) |
| Liraglutide | 26.8% (23.1–30.5) |
| Intensive lifestyle change | 26.2% (24.1–28.3) |
| Tirzepatide | 25.4% (22.8–28.0) |
| Lifestyle plus resistance training | 17.5% (14.2–20.8) |

Pooled estimates from 20 randomised trials, 15,782 participants. Heterogeneity was moderate (I-squared = 68 percent) and no publication bias was detected.

Read the table as a whole and the framing shifts. Muscle loss is a consequence of losing weight quickly, not a distinctive toxicity of GLP-1 drugs, and the single intervention that reliably moves the number is the one nobody can bottle. That is also the honest limit of the science right now: the Annals reviewers noted that not one of the 35 trials reported an objective measure of physical function. We can see the tissue leaving. We do not yet know, from trial data, what it costs people in strength or independence.

## What the evidence actually recommends

Both syntheses land in the same place — resistance training, adequate protein, and body-composition monitoring built into the weight-loss programme rather than sold alongside it. The first trial designed to test that combination specifically in GLP-1 patients is running now. LEAN-PREP, registered as NCT06885736 and published as a protocol in BMJ Open in April 2026, randomises 232 adults starting semaglutide or tirzepatide into four arms: control, home-based resistance exercise three times a week, protein supplementation, or both. Its primary outcome is quadriceps cross-sectional area on MRI at six months.

The protein target in that trial is instructive when you put it beside the products. LEAN-PREP aims for 1.6 grams per kilogram per day. For a 90-kilogram patient that is about 144 grams daily, of which a 35-gram shake covers roughly a quarter. A high-protein product is a reasonable tool for hitting a number that is genuinely hard to hit on a suppressed appetite. It is not, on current evidence, a substitute for the training half of the intervention — and the training half is the half the trials credit.

Amanda Avery, associate professor in nutrition and dietetics at the University of Nottingham, made the blunter version of the point to Reuters, noting that meat, fish, eggs, dairy, beans, nuts and pulses remain inexpensive sources of the same protein. She also expected the products to sell anyway.

## The same argument, in a peptide clinic

This is where the story stops being about groceries. "GLP-1 takes your muscle" is already the standard opener for selling growth-hormone secretagogues — sermorelin, ipamorelin, CJC-1295, sometimes tesamorelin — as a companion to a weight-loss prescription. The premise is borrowed from the same literature Nestle is citing. The conclusion is not.

We searched PubMed on August 18, 2026 for those peptides in combination with semaglutide, tirzepatide or GLP-1 drugs generally. Twenty-one records came back. Restricting to the Clinical Trial publication type returned nothing at all — no trial has tested whether adding one of these peptides to a GLP-1 protocol preserves lean mass, because the trial has not been run.

The most useful item among those 21 is a narrative review published in the Journal of Clinical Medicine in January 2026, surveying the drugs actually in development for this purpose. Its list is bimagrumab, an activin receptor agent; enobosarm, a selective androgen receptor modulator; and tesamorelin, a growth-hormone-releasing hormone analogue. Its verdict is that most of them sit "in the early phases of research development." Sermorelin, ipamorelin and CJC-1295 do not appear on that list at all.

That absence is the point. [Tesamorelin](https://peptidewellnessusa.com/peptides/tesamorelin/) is at least a real candidate — FDA-approved, with genuine body-composition data, though in HIV-associated lipodystrophy rather than in weight-loss patients. The peptides most often sold for muscle preservation are the ones with the least behind them; our pages on [CJC-1295](https://peptidewellnessusa.com/peptides/cjc-1295/) and [sermorelin](https://peptidewellnessusa.com/peptides/sermorelin/) set out what does and does not exist.

That is the useful thing about watching a food conglomerate enter this space. Nestle and a compounding clinic are working the same gap in the same evidence base, with very different regulatory exposure. A protein shake makes a nutrition claim and carries almost no risk to the buyer beyond price. An injectable prescribed off-label on the strength of the same argument is a different proposition, and the [questions worth asking a prescriber](https://peptidewellnessusa.com/learn/how-peptides-are-prescribed/) do not change because a household brand has validated the premise.

## What to do with this

If you are on a GLP-1 drug, the practical takeaways are unglamorous and well supported. Resistance training is the only intervention in the pooled data that meaningfully changed the lean-mass share. Protein intake in the region of 1.6 grams per kilogram per day is what the trials are testing, and hitting it with an appetite suppressant on board is the actual difficulty a high-protein product addresses. Ask whether body composition is being measured at all, rather than weight alone — none of this is visible on a scale.

The discontinuation question sits underneath all of it. In the STEP 1 trial extension, participants who had lost 17.3 percent of body weight regained 11.6 percentage points of it within a year of stopping, ending at 5.6 percent below baseline, with most cardiometabolic gains drifting back toward where they started. Weight comes back as fat more readily than as muscle. That, not "Ozempic face," is the strongest argument for taking the muscle question seriously — and it is an argument for training and monitoring, not for buying something. For the underlying pharmacology, see our pages on [semaglutide](https://peptidewellnessusa.com/peptides/semaglutide/), [tirzepatide](https://peptidewellnessusa.com/peptides/tirzepatide/) and the [GLP-1 class](https://peptidewellnessusa.com/peptides/glp-1/).

## References

1. [Reuters, Richa Naidu — "Nestle looks to develop new products to serve users of weight-loss drugs," August 17, 2026.](https://www.reuters.com/legal/litigation/nestle-looks-develop-new-products-serve-users-weight-loss-drugs-2026-08-17/)
2. [Nestle — Management and leadership (Stefan Palzer, Executive Vice President - Chief Technology Officer).](https://www.nestle.com/about/management)
3. [Nestle — Half-year results 2026 press release (checked for any GLP-1 or weight-loss-medication product line; none stated).](https://www.nestle.com/media/pressreleases/allpressreleases/half-year-results-2026)
4. [Batsis JA, Gavras A, Gross DC, et al. — "Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review." Annals of Internal Medicine, 2026;179(7):996-1013. PMID 41996180.](https://pubmed.ncbi.nlm.nih.gov/41996180/)
5. [Eisa N, Barood O — "Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials." Diabetes, Obesity and Metabolism, 2026;28(6):4818-4827. PMID 41877354.](https://pubmed.ncbi.nlm.nih.gov/41877354/)
6. [Wilding JPH, Batterham RL, Davies M, et al. — "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism, 2022;24(8):1553-1564. PMID 35441470.](https://pubmed.ncbi.nlm.nih.gov/35441470/)
7. [Alawadhi AA, Alroudhan D, Alsaeed DJ, et al. — "LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial." BMJ Open, 2026;16(4):e116911. PMID 42020128.](https://pubmed.ncbi.nlm.nih.gov/42020128/)
8. [ClinicalTrials.gov — LEAN-PREP trial registration, NCT06885736.](https://clinicaltrials.gov/study/NCT06885736)
9. [Arora G, Conde KR, Desouza CV — "Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss." Journal of Clinical Medicine, 2026;15(2):541. PMID 41598480.](https://pubmed.ncbi.nlm.nih.gov/41598480/)

> Editorial note: Informational only — not medical advice. Product and research claims described here are attributed to their sources; PeptideWellness has not tested any product mentioned and has no commercial relationship with any company named. Growth-hormone secretagogue peptides are not approved for muscle preservation during weight-loss drug therapy. Decisions about weight-loss or peptide therapy should be made with a licensed healthcare provider familiar with your medical history. Last reviewed August 2026.